Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved obinutuzumab in combination with CVP chemotherapy (cyclophosphamide, prednisolone, and vincristine) as a treatment option for the treatment of patients with previously untreated advanced follicular lymphoma. The treatment regimen further defines eligibility criteria as requiring previously untreated, CD20-positive follicular lymphoma (grade 1 to 3a) with advanced disease stage III, stage IV, or stage II with bulk disease [tumor >= 7 cm in the greatest dimension]), ECOG status 0-2, and adequate hematological, renal, and liver status.

This is written in the approval document as:

Obinutuzumab in combination with CVP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

Reimbursement

Incomplete Reimbursement

Obinutuzumab - ODMS 2019-05-01; cyclophosphamide and vincristine - N/A

Citation

Obinutuzumab cycloPHOSphamide vinCRIStine and prednisoLONE (O-CVP) Therapy - 21 day, Year, version number 3, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8394/550_obinutuzumab_CVP_550.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Obinutuzumab, Prednisolone, Vincristine

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2019-05-01	Health Service Executive	Indication approved for reimbursement.